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Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract (GIT).
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factors for CD, although the mechanisms involved are poorly understood. We employed a
mouse model of CS-induced experimental COPD and clinical studies to examine these
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Circulating vascular endothelial growth factor, a marker of systemic hypoxia, correlated with
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ischemia, driving angiogenesis and GIT epithelial barrier dysfunction, resulting in increased
risk and severity of CD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the third leading cause of  mortality and morbidity in 
the world, and its incidence is increasing (1). COPD describes a range of  pulmonary pathologies includ-
ing chronic bronchitis, small airway remodeling, and emphysema, which — in combination — result 
in reduced gas exchange and lung function (2, 3). Inhalation of  noxious particulates — in particular 
cigarette smoke (CS), but also wood smoke, cooking smoke, and air pollution— are major risk factors 
for the development of  COPD. Crohn’s disease (CD), one of  the 2 predominant forms of  inflamma-
tory bowel disease (IBD), is estimated to affect 0.5% of  the population in Western societies, and its 
prevalence is increasing globally (4, 5). CD is characterized by chronic mucosal inflammation of  the 
gastrointestinal tract (GIT) and compromised intestinal barrier function that gradually become more 
severe over time (6, 7). The etiology of  CD is incompletely understood, but genetic, environmental, and 
disease risk factors play an important role.
CS exposure is also a major environmental risk factor for CD, and the subsequent development of  
COPD further increases the risk of  CD. Smokers and COPD sufferers have 2 and 2.72 times greater risk 
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for CD, respectively (8, 9), and CS is associated with relapse and increased disease severity in CD patients 
(10). The GIT is increasingly recognized as a major site of  extrapulmonary dysfunction that may be rele-
vant to COPD patients (6, 11).
The mechanistic links between CS, COPD, and CD are poorly understood (6, 7). Several mechanisms 
have been proposed, including the effects of  CS components such as nicotine on barrier and endothelial 
function, oxidative stress, smooth muscle contractility, and microbiome changes; however, to date, exper-
imental data has not yet definitively supported these hypotheses (9, 11, 12). Recently, it was reported that 
COPD patients exhibit increased intestinal barrier permeability associated with reduced lung function, 
both during rest and following mild physical exertion (13).
To better understand mechanisms of  increased susceptibility to CD associated with CS and COPD, 
we employed a pathophysiologically relevant mouse model of  CS exposure and experimental COPD. We 
have previously demonstrated that exposure of  mice to mainstream CS for 8 weeks induces chronic airway 
inflammation, leading to pathology and altered lung function reminiscent of  COPD (2, 14–20).
Here, we demonstrate that chronic (8-week) CS exposure is associated with the induction of  impaired 
lung gas exchange capacity and systemic hypoxia using our preclinical model and clinical samples. 
Figure 1. Chronic CS exposure induces experimental COPD and impairs gas exchange in the lung. Mice were exposed through the nose only to CS for 8 
weeks to induce experimental COPD. (A) Bronchoalveolar lavage was performed and total airway leukocytes enumerated (n = 5). (B) Formalin fixed lung 
tissue was H&E stained and evaluated by histopathological scoring for the presence of inflammatory cells in peribronchial, perivascular, and alveolar regions 
(n = 6). (C) Representative H&E-stained tissue sections showing increased immune cell accumulation in peribronchial and perivascular areas of lungs of 
CS-exposed mice (scale bar: 50 μM). (D) Quantification of collagen deposition around small airways (perimeter ≤ 1,000 μM) indicating airway remodeling (n 
= 5). (E) Representative images of lung sections stained with Masson’s trichrome used for airway collagen quantification (scale bar: 50 μM). (F) CS-induced 
emphysema-like alveolar enlargement (n = 6-7). (G) Impaired lung function in terms of increased lung compliance and inspiratory capacity in experimental 
COPD (n = 6–7). (H) Mice were exposed to CS for 4 or 8 weeks to drive the development (4 weeks) and establishment (8 weeks) of experimental COPD, with 
reduced DFCO demonstrating impaired gas exchange in experimental COPD (n = 6). **P ≤ 0.01, ***P ≤ 0.001 air vs. smoke. Student’s unpaired 2-tailed t test 
used for comparisons of 2 groups, 1-way ANOVA with Tukey’s post-hoc was used whenever more than 2 experimental groups were compared.
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We also provide evidence that systemic hypoxia may act as a novel driver of  intestinal pathologies that 
underpin the increased incidence and severity of  CD reported in smokers and COPD patients.
Results
Chronic CS exposure results in lung pathology and impairment of  gas exchange. We initially sought to determine 
whether our mouse model of  chronic CS exposure might be useful as a preclinical model for under-
standing the links between smoking and CD. As expected, and as occurred in our previous studies (2, 
14–20), mice that were exposed to CS for 8 weeks developed features of  experimental COPD, including 
increased cellular inflammation in the airways (Figure 1A) and lung tissue (Figure 1, B and C); remod-
eling of  small airways, including deposition of  collagen and epithelial layer thickening (Figure 1, D and 
E); emphysema-like alveolar enlargement (Figure 1F); and reduced lung function (Figure 1G) compared 
with normal air–exposed controls.
For this study we established a potentially novel technique, the diffusing factor for carbon monoxide 
(DFCO) to assess gas exchange in the lungs (21). Air-exposed control mice had DFCO values of  0.750 ± 0.014 
and 0.758 ± 0.013 at 4 and 8 weeks, respectively (Figure 1H). CS-exposed groups had a marked reduction 
in DFCO (0.631 ± 0.017 and 0.479 ± 0.023 at 4 and 8 weeks of  CS exposure, respectively). Significantly, 
gas exchange was reduced at 4 weeks, which precedes the onset of  significant lung pathology in our model 
Figure 2. Chronic CS exposure results in mild/subclinical pathology in the colon. Mice were exposed to CS for 4 or 8 weeks. (A) Colons were excised, and 
length was measured and shown to be significantly shorter, demonstrating that remodeling has occurred in CS-exposed groups compared with normal 
air–exposed controls (n = 7). (B) Thickening of the mucosal layer or (C) the muscular layer underlying the mucosa, commonly observed in experimental 
colitis models, was not detected in CS-exposed groups (n = 4). (D) Gross crypt loss was not evident; however, restructuring of the crypt architecture was 
evident, with increased intercrypt distance following CS exposure (n = 6). (E) Increased numbers of lymphoid aggregates were observed in the mucosal 
layer of CS-exposed groups (n = 4). (F) mRNA levels of TNF-α, IFN-γ, and TGF-β were increased in the colons of CS exposed groups (n = 4–6), *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. Student’s unpaired 2-tailed t test used for comparisons of 2 groups, 1-way ANOVA with Tukey’s post-hoc was used whenever more than 2 
experimental groups were compared.
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(14). The greatest suppression of  DFCO was observed at 8 weeks, which coincides with the onset of  the hall-
mark disease features of  experimental COPD. These data suggest that chronic CS exposure progressively 
decreases the DFCO of  the lung, including in experimental COPD, and closely resemble the reduced diffus-
ing lung capacity for carbon monoxide (DLCO) observed in healthy smokers and COPD in humans (22, 23).
Chronic CS exposure results in the induction of  histological and inflammatory changes in the colon. We then assessed 
markers of colitis in our model. Colon shortening, a gross indicator of inflammation and tissue remodeling 
in rodent models of colitis (24), was evident in groups CS-exposed for 8 weeks compared with normal air–
exposed controls (Figure 2A). Despite this, histological analysis could not detect other typical features of exper-
imental colitis such as mucosal and muscular layer thickening (Figure 2, B and C) (25), although there were sig-
nificant increases in intercrypt distance (Figure 2D) indicating crypt architecture remodeling. There was also a 
tendency toward increased numbers of lymphoid aggregates in the colonic tissue (Figure 2E). Concordant with 
the induction of a mild colitic phenotype similar to that found in humans (26), mRNA expression of CD-asso-
ciated proinflammatory cytokines TNF-α, IFN-γ, and TGF-β was increased in the colon of CS-exposed groups 
after 4 and 8 weeks (Figure 2F). The TNF-α result did not reach statistical significance at 4 weeks, indicating 
that these gut changes take time to occur and may not reflect a simple response to CS exposure but may involve 
CS-induced pathology. Thus, the induction of hallmark features of experimental COPD and impaired gas 
exchange with CS exposure was accompanied by the induction of a mild colitic phenotype in the colon.
Figure 3. Chronic CS exposure triggers mucosal hypoxia and HIF-2 stabilization. (A) Representative photomicrographs showing colon tissue hypoxia 
using hypoxyprobe staining in normal air– and CS-exposed colon tissue (scale bar: 100 μM). (B) Increased levels of hypoxia in the colonic mucosal layer 
normalized to total nuclear material in mucosa was detected in CS-exposed mice (n = 4–6). (C) The percentage of epithelial vs. mucosal area that 
stained positive for hypoxyprobe was determined, and the ratio of these 2 values was calculated, demonstrating a significant shift in hypoxyprobe 
staining to the mucosal layer of the colon in CS-exposed mice (n = 4). (D) HIF-2α but not HIF-1α was increased in whole colon tissue lysates from mice 
exposed to CS for 8 weeks, 12 weeks, or 8 weeks followed by 4 weeks of normal air exposure. (E) Densitometry shows increased HIF-2α protein relative 
to TATA-binding protein (TBP) (n = 6). *P ≤ 0.05, **P ≤ 0.01. Student’s unpaired 2-tailed t test used for comparisons of 2 groups, 1-way ANOVA with Tukey’s 
post-hoc was used whenever more than 2 experimental groups were compared.
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Chronic CS exposure is associated with increased colonic tissue hypoxia. Full-thickness mucosal tissue hypox-
ia and altered mucosal microvasculature are common features of  IBD (27–29). To investigate whether 
increased systemic and colon tissue hypoxia was associated with experimental COPD, we employed the 
pimanidazole-based dye, hypoxyprobe, which forms immunochemically detectable adducts with thiol-con-
taining amino acids in hypoxic tissues (partial pressure of  oxygen [pO2] < 10 mm Hg) (30). In colons from 
normal air–exposed groups, tissue hypoxia was restricted to the luminal epithelial layer (Figure 3, A–C), 
as previously described (24, 31). In contrast, colonic tissue from CS-exposed groups exhibited an increased 
amount of  total hypoxyprobe signal, which was present throughout the mucosal layer, as opposed to being 
restricted exclusively to the lumenal epithelium.
Tissue hypoxia can drive the stabilization of  HIF proteins HIF-1α and HIF-2α, which subsequently 
orchestrate tissue-adaptive responses primarily through the regulation of  gene networks. We performed 
immunoblot analysis to test whether HIF-1α or HIF-2α were stabilized after 8 weeks of  CS exposure. While 
HIF-1α was not detectable in any samples tested (Figure 3D), we observed that HIF-2α protein was stabi-
lized in colon tissue extracts from mice after 8 weeks of  CS exposure compared with normal air–exposed 
controls (Figure 3, D and E).
Chronic CS exposure is associated with increased colonic mucosal vascularization and local expression of  angiogenic 
factors. Angiogenesis can be induced in tissues following hypoxia-mediated stabilization of  HIF proteins as 
part of  the adaptive response (32). We undertook a general histological evaluation of  colons after 4 and 8 
weeks of  CS exposure in mice and found that the mucosal vasculature was more extensive compared with 
those exposed to normal air (Figure 4A). To formally assess this, we performed immunohistochemistry to 
visualize mucosal vasculature with the panendothelial cell antigen MECA-32 (33) after 8 weeks of  CS expo-
sure (Figure 4B). Analysis revealed a higher frequency of  MECA-32–positive events per crypt and overall 
increases in the percentage of  mucosal tissue that stained positive (Figure 4C). Mean MECA-32–positive 
Figure 4. Chronic CS exposure drives vascularization and 
VEGF expression. Mice were exposed to CS for 4 or 8 weeks. 
(A) Increased mucosal vasculature was observed in the colons 
of CS-exposed groups after 4 and 8 weeks of CS exposure (n = 
6–8). (B) Vasculature was visualized by IHC against the MECA-32 
antigen (upper panels) and color deconvolution performed for 
quantitative analysis (lower panels) (scale bar: 100 μM). (C) The 
total number of discrete MECA-32–positive events increased 
with smoke exposure, as did the total proportion of mucosal tis-
sue that was MECA-32 positive. There was a nonsignificant trend 
toward increased MECA-32 event area following smoke exposure 
(n = 6). (D) Increased vasculature was accompanied by elevated 
mRNA expression of proangiogenic factors VEGF and iNOS in 
whole colon tissue (n = 5–6). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
Student’s unpaired 2-tailed t test used for comparisons of 2 groups, 
1-way ANOVA with Tukey’s post-hoc was used whenever more than 2 
experimental groups were compared.
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mucosal vessel area was also increased, although not to a statistically significant extent. Exaggerated vascu-
larization of  the CS-exposed colon was accompanied by increases in the expression of  mRNA of  proangio-
genic VEGF and inducible nitric oxide synthase (iNOS), both of  which are HIF-inducible target genes (34), 
after 4 and 8 weeks of  CS exposure (Figure 4D).
Chronic CS exposure is associated with altered cellular turnover and decreased barrier function in colons. Tissue 
hypoxia and cytokines such as TNF-α are known triggers of  cell death and turnover in the GIT (13, 35). His-
tological evaluation revealed that chronic CS exposure resulted in increased numbers of  mitotic cell profiles 
in colon crypts compared with normal air–exposed controls (Figure 5A). To quantify cell death in tissues, 
TUNEL analysis was performed, which revealed an approximately 2-fold increase in the number of  dead 
cells in the colons of  CS-exposed groups (Figure 5B). The majority of  these dead cells were located within 
the epithelial layer (Figure 5C). Increased death and damage of  the epithelial layer is known to compromise 
epithelial barrier function (36), and we hypothesized that the altered cellular turnover that was apparent in 
colons from CS-exposed mice could contribute to decreased barrier function. Importantly, intestinal perme-
ability assays showed that CS exposure increased intestinal permeability in the colon (Figure 5D). Interest-
ingly, increased colon permeability developed in a time-dependent manner and progressively increased after 
8 or 12 weeks of  CS exposure. Thus, increased colon barrier permeability was preceded by impaired gas 
exchange in the lungs (Figure 1H), mucosal hypoxia (Figure 3, A–C), inflammation (Figure 2, E and F), 
and angiogenesis (Figure 4, A–D) in the colon after 4 weeks. Furthermore, it developed with prolonged CS 
exposure (8–12 weeks) in tandem with the induction of  COPD-like lung pathology (14–20).
Chronic CS–induced pathological changes in the GIT extend to the ileum. CD affects all areas of  the GIT, in 
particular the ileum and colon, and smoking has been linked with increased incidence of  ileal pathology in 
CD patients (37, 38). Thus, we next assessed whether chronic CS exposure of  mice for 8 weeks resulted in 
development of  pathological changes in the ileum, like we observed in the colon. Chronic CS exposure was 
associated with increased levels of  tissue hypoxia in ileal tissue (Figure 6A). CS exposure and GIT mucosal 
tissue hypoxia were again also associated with measurable pathophysiologic changes in the ileum that were 
Figure 5. Chronic CS exposure induces altered cellular turnover and increased barrier per-
meability in the colon. Mice were exposed to CS for 4, 8, or 12 weeks to drive development 
(4 weeks), establishment (8 weeks), and progression (12 weeks) of experimental COPD. (A) 
After 8 weeks, increased numbers of mitotic nuclei were observed in the colonic crypts of 
CS-exposed groups (n = 6). (B) TUNEL staining was performed to evaluate the extent of cell 
death, and increased numbers of TUNEL-positive cells were observed in the epithelial and 
mucosal layers of colons from CS-exposed groups (n = 6). (C) Representative fluorescent 
microscopy images of TUNEL-stained colon tissue. Notably, high numbers of TUNEL-posi-
tive cells were observed in the epithelial layer of the colons of CS-exposed groups (scale bar: 
100 μM). (D) Increased colon barrier permeability was observed after 8 and 12 weeks of CS 
exposure (n = 4–6). *P ≤ 0.05, **P ≤ 0.01. Student’s unpaired 2-tailed t test used for com-
parisons of 2 groups, 1-way ANOVA with Tukey’s post-hoc was used whenever more than 2 
experimental groups were compared.
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indicative of  a mild disease state, including increased ratio of  crypt/villus length (Figure 6B) and villus wid-
ening (Figure 6, C and D) compared with normal air–exposed controls. mRNA expression of  inflammatory 
cytokines such as IFN-γ and TGF-β was also increased (Figure 6E), while TNF-α expression was unaffected 
(data not shown). Increased vascularization of  villi was also present (Figure 6, D and F). Vascularization 
was accompanied by increased mRNA expression of  the angiogenic factor VEGF, although — in contrast 
to the colon — the expression of  iNOS was unaffected (Figure 6G). Ileum barrier permeability was also 
increased (Figure 6H). Thus, chronic CS exposure, impaired lung gas exchange, and the induction of  a 
COPD-like phenotype in mice resulted in the induction of  a pathological profile in the GIT that extended 
from the colon into the ileum.
Smoking cessation has differential effects on pathological changes in the colon and ileum. In smokers, the cessa-
tion of  smoking reduces the incidence and severity of  CD (39). How smoking cessation affects CD incidence 
and severity in COPD patients is not understood. To explore this, we exposed mice to CS for 12 weeks, at 
which time COPD-like lung pathology has further developed compared with 8-week exposure (14). Other 
groups were CS-exposed for 8 weeks, followed by smoking cessation and 4 weeks of  normal air exposure. 
We previously demonstrated that COPD-like pathology such as emphysema persists following this smok-
ing cessation period, as does the increased presence of  macrophages in the airways (14). In the colon, the 
persistence of  changes in immune and vascular-related factors varied following smoking cessation. After 
smoking cessation, TNF-α expression continued to increase, IFN-γ expression returned to baseline levels, 
Figure 6. Chronic CS–induced pathology 
extends to the ileum. Mice were exposed to CS 
for 8 weeks to induce experimental COPD. (A) 
Increased total mucosal hypoxyprobe signal 
was observed in the mucosal layer of ileum of 
CS-exposed groups (n = 5). (B and C) Increased 
crypt/villus length ratio and villus width in 
ileum of CS-exposed mice (n = 4). (D) Represen-
tative photomicrographs of H&E-stained ileum 
from normal air– and CS-exposed mice showing 
altered villus architecture and increased vas-
culature in CS-exposed groups (scale bar: 100 
μM). (E) qPCR analysis of inflammatory genes 
indicated that IFN-γ mRNA was increased in 
the ileum of CS-exposed groups, while TGF-β 
expression was unaltered (n = 6). (F) Vascula-
ture and (G) VEGF but not iNOS mRNA were 
increased in the ileum of CS-exposed groups (n 
= 4–6). (H) Reduced epithelial barrier function 
of the ileum was observed in CS-exposed groups 
(n = 5). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Stu-
dent’s unpaired 2-tailed t test used for comparisons 
of 2 groups, 1-way ANOVA with Tukey’s post-hoc 
was used whenever more than 2 experimental 
groups were compared.
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and TGF-β was not upregulated after 12 weeks of  smoking or following smoking cessation (Figure 7A). 
HIF-2α stabilization remained evident after 12 weeks of  CS exposure and was still present after smoking 
cessation (Figure 3D). Consistent with this, smoking cessation reduced the total amount of  mucosal vas-
cular tissue compared with continued CS exposure, although vascular area and density remained elevated 
compared with normal air–exposed controls (Figure 7B). VEGF expression decreased following smoke ces-
sation, although not consistently; however, iNOS expression significantly increased (Figure 7C), confirming 
an altered inflammatory environment in the colon following smoking cessation. In contrast, CS-induced 
pathology of  the ileum resolved following smoking cessation, with the levels of  expression of  IFN-γ and 
TGF-β (Figure 7D), vascularisation of  villi (Figure 7E), and VEGF and iNOS expression (Figure 7F) all 
returning to air-exposed control levels. Thus, with smoking cessation, some inflammatory and pathological 
features remained or progressed in the colon, while most CS-associated changes resolved in the ileum.
The pan-PHDi DMOG rescues chronic CS–induced GIT pathology independently of  lung pathology. Tissue hypox-
ia is an important feature of  colitis and has been shown to trigger epithelial layer damage and increased per-
meability in the GIT (29). Our data suggest a scenario whereby the combination of  CS exposure and reduced 
Figure 7. Smoking cessation alters pathology in the colon and ileum. 
Mice were exposed to CS for 8 weeks to induce experimental COPD and 
then breathed normal air or continued CS exposure for 4 weeks. (A) qPCR 
assessment of mRNA showed that TNF-α expression increased, IFN-γ 
expression decreased, and TGF-β expression was unaltered in whole 
colons with smoking cessation (n = 5–6). (B) Smoking cessation resulted 
in nonsignificant decreases in the number of and volume of blood vessels, 
and a significant decrease in total MECA-32–positive mucosal area in 
colons compared with groups continually exposed to CS for 12 weeks (n = 
4–6). (C) VEGF mRNA was increased in the colon following 12 weeks but 
not following smoking cessation, while iNOS was significantly increased in 
the colon following smoking cessation (n = 5–6). (D) mRNA levels of IFN-γ 
and TGF-β returned to baseline in the ileum following smoking cessation 
(n = 4–6). (E) Smoking cessation reversed the increased vascularization 
of ileal tissue (n = 4–6). (F) VEGF and iNOS expression were increased in 
the ileum of the 12-week CS-exposed group but not following smoking 
cessation (n = 4–6). *P ≤ 0.05, **P ≤ 0.01. Student’s unpaired 2-tailed t test 
used for comparisons of 2 groups, 1-way ANOVA with Tukey’s post-hoc was used 
whenever more than 2 experimental groups were compared.
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gas exchange and lung function in experimental COPD may result in the development of  a chronic hypoxic 
state in the GIT. This may lead to the activation of  HIF-2–associated signaling and attempted compensatory 
vascularization of  the affected mucosal tissue. The data presented above show that, despite increased vascu-
larization, elevated tissue hypoxia persisted in the mucosal layer, which could be an important driver of  cell 
death, inflammation, and increased intestinal permeability in the GIT following CS exposure (Figure 2–7). 
Thus, we examined the effects of  suppressing tissue hypoxia and increased barrier permeability, and there-
fore CD-like pathology, with a targeted pharmacological intervention. Prolyl hydroxylase domain inhibitors 
(PHDis) have been investigated as potential therapeutic agents in IBD and have protective effects in exper-
imental models of  colitis, including the prevention of  colitis-associated increased gut permeability (24, 25). 
To assess the therapeutic potential of  PHDis in CS-induced CD-like features, we systemically (i.p.) treated 
mice with the pan-PHDi dimethyloxaloylglycine (DMOG) during the course of  8 weeks of  CS exposure and 
examined the effects on lung and GIT pathology. DMOG treatment had no significant effect on cellular and 
molecular inflammation or pathology in the lung induced by chronic CS exposure. There were no effects on 
CS-mediated increases in leukocyte, macrophage, neutrophil, and lymphocyte influx into the airways (Sup-
plemental Figure 1, A–D; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.94040DS1); upregulation of  key macrophage and neutrophil chemokines MCP-1 and CXCL1; 
Figure 8. DMOG treatment during chronic CS exposure prevents 
pathology in the colon. Mice were exposed to CS for 8 weeks to 
induce experimental COPD and were treated with DMOG through-
out. (A) Tissue hypoxia was measured using hypoxyprobe, and 
DMOG treatment partially prevented the mucosal hypoxic pheno-
type in colons of CS-exposed mice (n = 3–4). (B) DMOG treatment 
partly prevented increases in TNF-α and TGF-β mRNA expression 
in the colon (n = 4–6). (C) DMOG treatment inhibited increases 
in vasculature (n = 5–6). (D and E) DMOG treatment increased 
the mRNA expression of HIF target genes VEGF, iNOS, CD73, and 
gravin in the colons of CS-exposed groups (n = 4–6). (F) DMOG 
treatment completely inhibited increases in crypt mitoses (n = 
5–6). (G) DMOG treatment completely inhibited the CS-induced 
increases in colon barrier permeability in CS-exposed mice (n 
= 4–6). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Student’s unpaired 
2-tailed t test used for comparisons of 2 groups, 1-way ANOVA with 
Tukey’s post-hoc was used whenever more than 2 experimental groups 
were compared.
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or matrix metalloprotease (MMP)12 levels (Supplemental Figure 1E). CS-induced emphysema–like alveolar 
enlargement was also unaffected by DMOG treatment (Supplemental Figure 1F). In contrast, examination of  
the altered hypoxyprobe staining in the colon revealed that, in most mice, DMOG prevented the significant 
reduction in CS-related hypoxia in the mucosal layer relative to the epithelial layer, compared with the vehi-
cle-treated group, and there was a nonsignificant trend toward protection compared with the vehicle-treated 
CS-exposed group (Figure 8A). DMOG treatment prevented the increases in expression of  CD-associated 
inflammatory genes TNF-α and TGF-β in CS-exposed mice (Figure 8B). In addition, the increased vascu-
lature that characterized CS-exposed colonic mucosal tissue was also not present in DMOG-treated mice 
(Figure 8C). Despite this, DMOG treatment further upregulated colonic VEGF expression in CS-exposed 
groups (Figure 8D). As VEGF is an HIF-1 and HIF-2 target gene, it was not unexpected that DMOG treat-
ment would further increase its expression; indeed, the expression of  other known HIF-1 target genes such as 
iNOS, CD73, and gravin were also increased (Figure 8E). DMOG treatment was associated with complete 
protection against altered crypt cell turnover (Figure 8F). Most importantly, DMOG treatment completely 
prevented CS-induced increases in colon permeability (Figure 8G). In summary, systemic treatment with the 
PHDi DMOG suppressed colon hypoxia and associated pathology in CS-induced experimental COPD.
Smoke exposure predisposes to more severe TNBS-induced colitis. Tobacco smokers have a higher incidence 
of  CD, as well as worse disease progression, compared with nonsmokers (6). The heightened risk of  CD 
observed in smokers is further elevated in COPD patients. Our data indicate that chronic smoke exposure 
resulted in a range of  pathological changes to the GIT, and we hypothesized these changes would sensitize 
to a subsequent colitis-inducing challenge. To test this, we assessed the response of  CS-exposed mice to a 
well-characterized model of  2,4,6-trinitrobenzenesulfonic acid–induced (TNBS-induced) experimental colitis 
(40). It is likely that mice with experimental COPD would not survive a TNBS challenge. Thus, we exposed 
mice to CS for 4 weeks, at which time gas exchange in the lung was impaired and many pathological GIT 
changes were observed (Figures 1–4), and then challenged them with TNBS while ceasing smoke exposure. 
As expected, TNBS caused a marked induction of  CD-like pathology, indicated by increases in histological 
Figure 9. Chronic CS exposure predisposes to 
TNBS-induced experimental colitis. Mice were 
exposed to CS for 4 weeks, followed by the induc-
tion of colitis with TNBS. (A) Histological inflam-
matory scoring of H&E sections revealed that CS 
exposure resulted in a more severe colitic pheno-
type in response to TNBS, although (B) a further 
shortening of the colon did not occur (n = 4–5). (C) 
Representative micrographs of H&E-stained colon 
sections from normal air–exposed TNBS–treated 
and CS-exposed TNBS-treated mice. Colons from 
CS-exposed TNBS-treated mice displayed greater 
mucosal inflammatory infiltration and crypt dys-
plasia (scale bar: 100 μM). (D) Expression of iNOS, 
VEGF, TGF-β, and TNF-α in mice exposed to normal 
air or CS ± vehicle or TNBS (n = 3–6). *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. Student’s unpaired 2-tailed t 
test used for comparisons of 2 groups, 1-way ANOVA 
with Tukey’s post-hoc was used whenever more than 2 
experimental groups were compared.
1 1insight.jci.org   https://doi.org/10.1172/jci.insight.94040
R E S E A R C H  A R T I C L E
inflammatory score (Figure 9A) and colon shortening (Figure 9B). Prior CS exposure exaggerated the severity 
of  pathology induced by TNBS with further increases in histopathological score (Figure 9, A and C). We also 
examined the expression of  TNF-α, TGF-β, VEGF, and iNOS (Figure 9D), which showed trends toward 
further increased expression in CS-exposed TNBS-treated mice compared with normal air–exposed controls. 
Expression of  other colitis-associated cytokines IL-6 and IL-12p40 showed a similar trend toward highest 
expression in CS-exposed TNBS-treated mice compared with other groups (data not shown). Thus, CS expo-
sure predisposed to the development of  a more severe phenotype of  colitis in our TNBS model, which sup-
ports the epidemiological data linking smoking, COPD, and increased CD severity.
Smoking and CD are associated with elevated serum VEGF and GIT mucosal vasculature in humans. Cigarette 
smoking and associated systemic hypoxia have been linked to elevated peripheral levels of  VEGF in the 
context of  lung and liver disease (41–43). We found that serum VEGF levels were increased in mice fol-
lowing chronic smoke exposure and smoking cessation and in association with the development of  CD-like 
features (Figure 10, A and B). We then sought to validate our findings in preclinical mouse models in clinical 
samples from current smokers, former smokers, and never-smokers with CD compared with subjects who 
were considered healthy. CD patients had elevated serum VEGF levels compared with healthy participants, 
as previously reported (Figure 10C) (44). Importantly, both current and former smokers had significantly 
elevated VEGF levels compared with never-smokers (Figure 10D). When stratified by disease and smoking 
status, current and former smokers with CD had significantly increased VEGF, with trending increases in 
Figure 10. Serum VEGF is elevated in mice chronical-
ly exposed to CS and in current and former smokers 
with CD. (A) Mice were exposed to normal air or CS 
for 12 weeks or CS for 8 weeks followed by 4 weeks 
normal air. Immunoblotting of serum for VEGF. (B) 
Densitometric analysis of immunoblotting revealed 
elevated levels of serum VEGF in CS-exposed groups 
compared with normal air–exposed controls (n = 3). 
(C) Serum VEGF was elevated in the serum of human 
CD patients compared with healthy controls (n = 12). 
(D) Serum VEGF is elevated in smokers and ex-smok-
ers compared with never-smokers (both healthy and 
CD) (n = 8). (E) Current or former smokers with CD 
show significantly elevated serum VEGF (n = 4). (F) 
Total CD34 signal as a percentage of tissue area in 
surface mucosal biopsies from the terminal ileum of 
healthy nonsmoker, healthy smoker, CD nonsmoker, 
and CD smoker patients was quantified (n = 2–3). (G) 
Representative photomicrographs of terminal ileum 
mucosal biopsies stained for CD34 (scale bar: 50 μM). 
*P ≤ 0.05, **P ≤ 0.01. Student’s unpaired 2-tailed t 
test used for comparisons of 2 groups, 1-way ANOVA 
with Tukey’s post-hoc was used whenever more than 
2 experimental groups were compared.
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current and ex-smokers of  healthy status (Figure 10E). We also performed histological analysis of  mucosal 
biopsies of  ileum taken from healthy or CD patients, stratifying on the basis of  smoking status. We observed 
increased mucosal vascularity in the ileum of  smokers with CD compared with nonsmokers, supporting our 
preclinical model findings (Figure 10, F and G). These data suggest that smoking induces lasting effects on 
systemic VEGF, a marker of  systemic hypoxia, that is highest in current and former smokers suffering from 
CD and could contribute to colonic remodeling, as evidenced by increased mucosal vasculature.
Discussion
Epidemiological evidence suggests that GIT symptoms are highly prevalent among smokers and COPD 
patients, and that smoking and COPD are associated with higher risks of  CD compared with nonsmokers 
(6). The mechanistic links between smoking and CD are poorly understood, and those linking COPD to 
IBD have barely been explored. Here, we identify mechanisms by which chronic smoke exposure and 
smoke-induced lung diseases, such as COPD, influence intestinal integrity and may predispose to chronic 
intestinal conditions such as CD. Using a preclinical mouse model, we show for the first time to our knowl-
edge that chronic inhalational smoke exposure induces impaired gas exchange and pathology in the lung. 
This leads to hypoxia in the GIT; stabilization of  HIF-2α; ischemic damage in the intestine with colon 
remodeling, inflammatory responses, and increased microvascular density; and exaggerated barrier perme-
ability. This pathology extends to the ileum, a critical site of  CD lesions associated with smoking. Smoking 
cessation reverses pathology in the ileum and, to a lesser extent, the colon. Importantly, CS-induced GIT 
pathology could be suppressed by systemic PHDi treatment independently of  lung pathology. CS-induced 
gut pathology primed for and increased the severity of  experimental colitis. Our preclinical findings are val-
idated by data from clinical samples that establish a correlation between smoking status, systemic hypoxia, 
and CD, as well as increased mucosal vasculature in the terminal ileum of  CD patients that smoke. Based 
on these findings, we propose a model whereby chronic CS exposure, and resulting COPD, impair pulmo-
nary gas exchange resulting in systemic hypoxia. GIT hypoxia and HIF-2α stablilization drive angiogen-
esis and epithelial cell damage, impairing epithelial barrier function and setting up a cycle of  increasing 
exposure and inflammatory reaction to lumenal antigens, which ultimately predisposes to and increases 
the severity of  CD. Indeed, there is likely to be a strong influence of  gut microbiota in CD and potentially 
COPD pathology (11). Gut-lung crosstalk, where changes in the microbiota or inflammatory responses in 
one organ can affect the other promoting distal inflammation, is now a well-established concept (11). We 
have observed substantial changes in microbial populations in the gut with CS exposure and the develop-
ment of  experimental COPD (unpublished data). Others have shown that chronic CS exposure of  mice 
altered microbial gut populations and the expression of  mucus genes in the colon (45).
We show here, for the first time to our knowledge in a preclinical model of  experimental COPD, 
that impaired pulmonary gas exchange is an early pathological change induced by chronic CS exposure. 
Impaired gas exchange was evident after 4 weeks of  CS exposure, prior to the development of  hallmark 
COPD pathologies such as airway remodeling, emphysema, and impaired lung function that appear after 
8 weeks (14). This observation is supported by a recent clinical study showing that smokers with impaired 
gas exchange but normal spirometry are more likely to develop COPD than smokers with normal gas 
exchange and spirometry (22). Collectively, these studies suggest that impaired gas exchange may precede 
the induction of  COPD pathology.
Impaired gas exchange induced by smoking has long been associated with systemic hypoxia. Indeed, 
polycythemia is a well-established consequence of  heavy smoking, as the body attempts to compensate for 
reduced oxygen availability by increasing production of  oxygen-carrying RBCs (46–48). Our finding that 
serum VEGF, a cytokine and marker of  systemic hypoxia (41–43), is increased in both preclinical and clin-
ical samples in current and former smokers is suggestive that chronic CS exposure can induce long-lasting 
systemic effects. Increased serum VEGF in CD has been reported previously (44). Our observations of  
the effects of  current or former smoking in increasing serum VEGF in CD patients (and to a lesser extent 
healthy patients) supports our hypothesis that smokers that develop impaired gas exchange and systemic 
hypoxia are at higher risk of  developing CD. Further studies are required to examine serum in COPD 
patients with or without CD, where we hypothesize that further impairment of  lung function would lead to 
greater increases in systemic hypoxia.
Our observations of  impaired gas exchange in the lung and increased circulating VEGF prompted us 
to investigate whether intestinal oxygen levels may be perturbed after chronic CS exposure. Histological 
1 3insight.jci.org   https://doi.org/10.1172/jci.insight.94040
R E S E A R C H  A R T I C L E
analysis of  hypoxia-dependent pimonidazole retention revealed the development of  transmural hypoxia 
in CS-exposed mice, as opposed to the epithelial localization of  hypoxia in the normal gut (24, 31). In 
support of  this role for smoking-associated GIT hypoxia, laser doppler analysis of  smokers demonstrated 
a decrease in rectal blood flow within 30 minutes of  smoking (49). CD is a transmural disease associated 
with tissue ischemia (28) and maladaptive angiogenesis (27, 50), and it has been proposed that the cyclic 
nature of  GIT inflammation in CD can lead to incomplete neovascularization, hindering recruitment of  
inflammatory cells and production of  inflammatory mediators (51, 52). Thus, chronic smoke exposure 
may accelerate these processes, and indeed, in our animal model, smoking led to a more severe pathology 
in a subsequent TNBS model of  colitis.
Tissue hypoxia can result in stabilization of  HIF proteins HIF-1α and HIF-2α, which orchestrate adap-
tive responses to hypoxia through transcriptional activation of  target genes. It is increasingly recognized that 
HIF-1α and HIF-2α, although sharing redundant functions, are distinct in their modes of  activation, the 
downstream signaling they engage, and the biological outcomes of  the responses they mediate (53). HIF-1α 
becomes acutely activated during episodes of  severe hypoxia, and its activity does not persist beyond the ini-
tial hypoxic insult, while HIF-2α appears to be activated under conditions of  mild or physiological hypoxia 
in a prolonged manner. This distinct activation profile fits with a model based on our findings whereby grad-
ual deterioration of  lung function over a long period of  CS exposure results in chronic and mild systemic 
and tissue hypoxia, resulting in selective activation of  HIF-2α. HIF-1α and HIF-2α also appear to regulate 
overlapping and distinct gene networks, and our observation that VEGF (but not other known HIF-1α tar-
gets such as CD73 and gravin) is induced in the colons of  CS-exposed mice fits with prior observations that 
HIF-2α is the dominant isoform in the regulation of  VEGF (54). Selective activation of  HIF-2α observed in 
the colons of  CS-exposed mice also provides a potential mechanistic explanation for the link between smok-
ing and colorectal cancer (55), as HIF-2α may have roles in promoting tumorigenesis (54).
The GIT is highly susceptible to ischemia, largely due to the nature of  oxygen exchange in the villous 
microvascular system, which results in a steep descending oxygen gradient from the villus base to the tip 
(56). Thus, intestinal ischemic disease is commonly associated with diseases that limit blood flow, such as 
chronic renal failure and atherosclerosis (57). Angiogenesis in colitis is linked to increased expression of  
VEGF (58). VEGF-targeting therapies suppress angiogenesis and inflammation in animal models of  colitis 
(59). While we found that VEGF was upregulated in the serum and GIT following chronic CS exposure, 
pharmacological intervention with DMOG prevented angiogenesis while further increasing the expression 
of  HIF target VEGF. Thus, experimentally, the upregulation of  VEGF signaling does not appear to be suf-
ficient to drive angiogenesis, and other as yet unidentified factors may play a role, possibly in combination 
with VEGF. Regardless of  the role of  VEGF, our observations demonstrating increased vascularization 
associated with smoking status in human CD ileal biopsy samples validate our findings in our preclinical 
model and suggest that aberrant angiogenesis is a key feature of  smoking-associated GIT disease.
Epithelial apoptosis and increased permeability are pathologies commonly associated with intestinal 
ischemia (60). Our data indicate that colonic changes such as hypoxia and angiogenesis occurred early, 
along with the impairment of  gas exchange in the lung, but that intestinal barrier dysfunction developed 
concurrently with the establishment of  pulmonary pathology induced by chronic CS exposure and was not 
present after 4 weeks of  CS exposure. After 4 weeks of  CS exposure, inflammation is firmly established in 
the lungs; however, hallmark pathologies such as airway remodeling and emphysema have not yet devel-
oped (14). We propose 2 possible explanations for this apparent delay in onset of  GIT barrier dysfunction 
relative to other pathologies: that chronic impairment of  gas exchange resulting in GIT hypoxia and pathol-
ogy may result in accumulating epithelial damage and delayed intestinal barrier dysfunction, or alternative-
ly, that more severe lung pathology is needed to induce it, rather than inflammation or CS alone. In support 
of  the latter hypothesis, Rutten and colleagues recently described a link between COPD and IBD demon-
strating in a small controlled patient group that COPD patients displayed increased gut permeability at rest, 
which was further exacerbated after mild exertion along with markers of  systemic anaerobic metabolism 
(13). Collectively, these studies suggest that impaired gas exchange associated with smoking and COPD 
result in exaggerated systemic hypoxia, which can drive or further exacerbate intestinal barrier dysfunction.
Epithelial cell properties and fate are important determinants of  intestinal barrier function, and exag-
gerated epithelial cell death appears sufficient to trigger severe intestinal inflammation (61). Important 
in the context of  CD, a previous history of  smoking is a major risk factor for disease in late-onset CD. 
While CD generally presents in young adults, emphysema and COPD are diagnosed much later; however, 
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impaired gas exchange and subclinical pulmonary damage induced by smoking may manifest much earlier. 
The threshold of  lung damage required to induce GI pathology has not been defined. However, popula-
tion analysis has identified an increased risk for IBD in COPD patients (8). Smoking-induced barrier dys-
function provides a potential mechanism for other extrapulmonary pathologies associated with smoking. 
Smokers are at increased risk of  nonalcoholic fatty liver disease (NAFLD), and CS exposure also increases 
the severity of  established disease (62, 63). Importantly, increased mucosal permeability is thought to be 
an initiating factor in NAFLD, and patients have demonstrated both reduced epithelial barrier function 
and endotoxemia (64). Similarly, endotoxin has been shown to induce an initiating pancreatic injury in 
murine models of  alcohol-induced chronic pancreatitis (65), and current smokers are at an increased risk 
of  developing this disease (66, 67). Thus, smoking-associated increases in GIT mucosal permeability may 
contribute to the initiation or exacerbation of  these chronic diseases.
The decline in gas exchange capability and pulmonary function due to smoke exposure is currently irre-
versible, and smoking cessation merely delays or halts the progression of  COPD. While smoking cessation 
reverts the risk of  developing CD to baseline levels in general, the effects of  smoking cessation on CD risk 
in COPD patients has not been reported (8). In our model, smoking cessation following the establishment 
of  experimental COPD ameliorated GI pathology in the colon and ileum to different extents. In the colon, 
cessation led to reduction in IFN-γ mRNA and partially reduced vasculature, but it was associated with 
sustained HIF-2α stabilization and increased TNF-α and iNOS expression. In the ileum, cessation led 
to the resolution of  inflammation and microvascular density. Incomplete inflammatory resolution in the 
colon may be due to the difference in basal oxygen tensions between the colon and ileum (68), as well as the 
added metabolic stress of  the colonic microbiota (69). Moreover, the tendency toward a greater resolution 
of  ileal pathology following smoking cessation may be clinically reflective of  the ileal improvement in the 
majority of  CD patients that benefit from smoking cessation (39).
Pharmacological activation of  HIF-associated adaptive hypoxia responses is a promising exper-
imental strategy for the treatment of  IBD (25, 40). While many studies of  these PHDi compounds 
employ targeted delivery and selective activation pathways, we have previously shown that the pan-
PHDi DMOG acts systemically, increasing erythropoietin (EPO) and hematocrit, while also offering 
localized protection against inflammation in the GIT (25). Administration of  DMOG during CS expo-
sure partially prevented the COPD-associated mucosal hypoxic phenotype and reduced increases in 
microvascular density, epithelial cell turnover, and impairment of  barrier function. While colon muco-
sal layer hypoxia was reduced, systemic treatment did not affect pulmonary features in experimental 
COPD. Thus, the prevention of  colon mucosal hypoxia was unlikely to be due to a protective effect of  
DMOG in the lung, but it may reflect an increased oxygen carrying capacity of  the blood of  treated 
mice, resulting in more effective perfusion of  the colonic tissue. Increased expression of  hypoxia-adap-
tive responses may also account for the GIT-protective effects of  DMOG in experimental COPD, and 
further studies will be required to test this. A prior study demonstrated selectivity of  DMOG toward 
HIF-1α stabilization over HIF-2α, which may provide an additional mechanism whereby DMOG exerts 
barrier-protective effects in our model (70). Additional studies will also be needed to assess the local 
benefits of  suppressing hypoxia in the lung on COPD pathogenesis.
Many other mechanisms could be involved in the links between pulmonary pathology and the GIT. 
These could involve other systemic responses such as conditioning of  the BM, widespread and transport-
able inflammatory factors such as microRNAs and inflammasomes/ASC specks could be involved, and 
events may be exaggerated by infectious exacerbations of  pulmonary disease (16, 71–73). These potential 
pathogenic processes could be examined using combinations of  animal models and clinical studies.
In summary, we have demonstrated a potentially novel mechanism for the development of  patho-
physiologically relevant alterations in the colon and ileum during chronic inhalational CS exposure and 
development of  COPD, reflective of  clinical observations. The CS-induced impaired gas exchange and 
pulmonary pathology may promote systemic hypoxia, along with the induction of  intestinal hypoxia, 
inflammation, mucosal angiogenesis, and epithelial cell death and reduced intestinal barrier function, 
which are all likely to contribute to increased susceptibility to CD. Our results support and expand on 
the limited existing mechanistic data regarding the link between smoking, COPD, and CD and highlight 
the potential of  targeted therapeutic interventions such as hydroxylase inhibitors for the treatment of  
smoking-associated GIT dysfunction.
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Methods
Experimental COPD. WT female C57BL/6 mice (Australian BioResources) were exposed to the smoke of  
12 cigarettes (3R4F reference cigarettes; University of  Kentucky, Lexington, Kentucky, USA) twice/day, 
5 times/week for up to 12 weeks as previously described (14–18). An in-house custom-designed and pur-
pose-built nose-only, directed flow inhalation and smoke-exposure system (CH Technologies) was used to 
expose the mice to mainstream CS. Controls were exposed to normal air. For smoking cessation experi-
ments, mice were exposed to CS for 8 weeks and then normal air for a further 4 weeks.
DMOG treatment and TNBS model. The pan-PHDi DMOG (Cayman Chemicals) was dissolved in sterile 
PBS and administered i.p. (8 mg) every other day prior to CS exposure (3× weekly) as previously described 
(74). Control animals were administered injections of  sterile PBS alone. CS-exposed and control mice were 
exposed to TNBS as previously described (40).
Airway inflammation, remodeling, and emphysema. Airway inflammation was quantified by enumera-
tion of  macrophages, neutrophils, and lymphocytes in bronchoalveolar lavage fluid (BALF) as previously 
described (3, 14, 16–18). For histological analysis, lung tissue was fixed in formalin prior to mounting, sec-
tioning, and staining with H&E for assessment of  lung histopathology and emphysema. For analysis of  air-
way remodeling, the thickness of  the epithelial layer was measured in airways with a basement membrane 
perimeter < 1,000 μm (14, 19). Area of  collagen deposition around these airways was quantified using 
Masson’s trichrome–stained lung sections with ImageJ software (NIH) and color deconvolution processing 
(15, 19, 75). Emphysema was evaluated using the mean linear intercept technique, a standard method for 
examining alveolar diameter and damage in rodent models of  lung damage (14–18, 76).
DFCO. A single-breath maneuver to assess DFCO was performed as described previously (21). Briefly, 
mice were anesthetized with ketamine (117 mg/kg) and xylazine (14.4 mg/kg, both from Troy Laborato-
ries), a tracheostomy with ligation was performed (14, 19, 76), and a 19-gauge cannula was inserted into 
the trachea. Lungs were inflated with 1 ml of  tracer gas mixture (0.318% Ne, 0.302% CO and balance air). 
Following a 9-second breath hold, 1 ml of  gas was withdrawn from the lung, diluted to 2 ml (total volume) 
with room air, and the concentrations of  Ne and CO were measured by gas chromatography (60-second 
gas analysis time; INFICON). The DFCO is defined as 1 – (CO9/COc)/Ne9/Nec), where the subscripts 9 and 
c refer to the concentrations of  gas after a 9-second breath-hold time and calibration gas injected, respec-
tively. The DFCO is a dimensionless variable expressed as a value between 0 and 1; complete uptake of  CO 
is equal to 1, and no uptake of  CO is equal to 0.
Colon and ileum histopathology. Following euthanasia, entire colons were excised and fecal matter removed 
by gentle flushing with saline. Whole colons were fixed in formalin prior to paraffin embedding for slicing, 
staining (H&E), and histological evaluation (25, 40). For quantitative PCR (qPCR) analysis, a longitudinal 
section of  an entire length of  colon was snap frozen and stored at –80°C for subsequent RNA purification.
RNA extraction, cDNA synthesis, and qPCR analysis. Freshly excised lung, colonic, and ileal tissues were 
snap frozen for subsequent storage at –80°C. RNA was prepared from colon and ileum using a previously 
described protocol (14–18). Tissue was thawed and homogenized (1 ml of  TRIzol, 4°C; ThermoFisher 
Scientific) using a tissue-tearor homogenizer (Biospec). DNA was precipitated by chloroform addition, 
followed by centrifugation (12,000 g, 15 minutes), and the RNA-containing aqueous phase was collect-
ed. RNA was precipitated by addition of  Isopropyl alchohol and pelleted prior to 2 washes with 75% 
ethanol. RNA pellets were dissolved in nuclease-free water, and RNA purity and quantity were assessed 
using a Nanodrop spectrophotometer. For cDNA synthesis, RNA (1,000 ng per sample) was preincubated 
with 1 unit of  DNAse I (MilliporeSigma) (15 minutes, room temperature). Samples were heated (65°C, 
10 minutes) prior to the addition of  random hexamer primers (Bioline) and dNTPs (Bioline), and further 
heating (65°C, 5 minutes and 25°C, 10 minutes). Reaction buffer, DTT, nuclease-free water, and Bioscript 
reverse transcriptase (Bioline) were added, and reverse transcription was completed (10 minutes, 25°C; 50 
minutes, 42°C; and 15 minutes, 70°C). qPCR analysis was performed in 384-well plates with SYBR-green–
based detection using a Viia 7 Real Time PCR system (ThermoFisher Scientific). For mRNA quantification 
from lung tissue, specific mRNA products were expressed as relative abundance compared with hypox-
anthine-guanine phosphoribosyltransferase (HPRT), while — in colon and ileum tissue — mRNAs were 
expressed as abundance relative to β-actin expression.
IHC. For evaluation of  tissue hypoxia in the GIT the pimonidazole-based probe Hypoxyprobe (Hypoxy-
probe) was used as previously described (24, 31). Hypoxyprobe was administered (60 mg/kg, i.p.) 20 min-
utes prior to sacrifice. Hypoxyprobe signal was detected following the manufacturer’s instructions. Briefly, 
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paraffin embedded tissue slices were dewaxed and rehydrated prior to quenching of  tissue peroxidases in 3% 
H2O2. Following antigen retrieval (standard citrate buffer, 20 minutes, 95°C) slides were incubated (PBS + 
0.05% Tween [PBS-T], 5 minutes, 2×) before blocking (casein blocking buffer, 1 hour, room temperature). 
Slices were then incubated with primary antibody (1:50 in PBS-T, 40 minutes, room temperature). Second-
ary antibody was HRP-conjugated rabbit anti-mouse (MilliporeSigma, A9044, 1:200 in PBS-T). Hypoxy-
probe related signals were visualized by incubating tissue slices in DAB chromogen (Dako, K3468) for equal 
lengths of  time. Tissues were counterstained with hematoxylin, dehydrated, and mounted for imaging. For 
quantification, color deconvoluted images were assessed using ImageJ software for total hypoxyprobe DAB 
signal. Total hypoxyprobe signal in epithelial and mucosal layers was expressed as a percentage of  epithelial 
and mucosal tissue that was hypoxyprobe positive. Additionally, the percentage of  hypoxyprobe-positive epi-
thelial and mucosal tissue was calculated separately and then expressed as a ratio of  epithelial vs. mucosal 
levels of  tissue hypoxia. Vasculature was visualized in a similar fashion using anti–mouse pan-endothelial 
cell antigen, clone MECA-32 primary antibody (Developmental Studies Hybridoma Bank, University of  
Iowa, Iowa City, Iowa, USA) and HRP-conjugated rabbit anti–rat HRP (Dako, P0162). The total number of  
individual MECA-32–positive events, percentage area of  the epithelial and mucosal layers that was MECA-
32 positive, and the average size of  MECA-32–labeled events was assessed.
TUNEL stain for cell death. For visualization and quantification of  cell death in tissues, TUNEL assays 
were performed using the DeadEnd fluorometric TUNEL system (Roche Diagnostics) following the manu-
facturer’s instructions. Formalin-fixed, paraffin-embedded tissue slices were dewaxed and dehydrated prior 
to further incubation (4% paraformaldehyde, 15 minutes). Tissue was incubated with 20 μg/ml Proteinase 
K, washed, and then incubated again in 4% paraformaldehyde. Samples were immersed in equilibration 
buffer (10 minutes) prior to addition of  the rTdT enzyme/nucleotide labeling mix and incubation (60 min-
utes, 37°C). The enzymatic reaction was terminated with 2× SSC buffer, nuclei were labeled with Hoechst 
33342 (5 μg/ml), and tissue slices were mounted in FluorSave (MilliporeSigma) for imaging.
Intestinal permeability assay. Permeability of  the colon and ileum was determined using a tissue sac meth-
od as previously described (77, 78). Briefly, following euthanasia, colonic and ileal tissues were excised and 
flushed with oxygenated Medium 199 (MilliporeSigma). One end of  the colonic or ileal sac was carefully 
tied off. A second knot was tied loosely 2 cm away from the first knot. Each sac was then filled with 250 μl of  
a solution of  1 mg/ml dextran-FITC (MilliporeSigma, FD4) dissolved in oxygenated Medium 199, and the 
second knot was tightened to create a sac. Excess tissue was removed, and the sacs were immersed in 15 ml 
of  Medium 199 (37°C). Bathing Medium 199 (100 μl) was sampled and replaced with fresh medium every 
15 minutes. After 120 minutes, sacs were cut open, and contents were sampled. FD4 concentration in media 
samples was measured using a FLUOstar microplate reader (BMG Labtech). Velocity of  escape of  FD4 
across the intestinal layer was calculated to yield the apparent permeability of  the colon and ileum to FD4 
(Papp) using the equation Papp (cm s
–1) = (dQ/dt)/(ACo), where dQ/dt is the transport rate (mols–1 of  FD4), A is 
the surface area of  the sac (cm2), and Co is the initial concentration of  FD4 injected into the sac (mol ml–1).
Patient recruitment and human clinical samples. Twelve patients with CD were recruited at Royal 
Brisbane and Women’s Hospital with a validated protocol-driven approach (79), and diagnosis was 
confirmed by histopathology. Twelve asymptomatic individuals undergoing colonoscopy for screening 
purposes, with no history of  gastrointestinal inflammatory disease, were recruited as control subjects. 
Patients were age and sex matched between groups. Patient ages ranged from 24–72 years of  age (Mean 
age, 47 years). Smoking status was recorded at time of  recruitment, with ex-smokers defined as those 
individuals who had abstained from smoking for at least 6 months prior to recruitment. Serum was 
collected from whole blood and stored at –80oC until analysis. Serum VEGF levels were measured by 
ELISA using R&D Systems Human VEGF DuoSet ELISA Kit, as per the manufacturer’s instructions. 
For clinical biopsy samples of  terminal ileum, tissue was formalin fixed and embedded in paraffin. Vas-
culature was visualized through detection of  CD34 (Leica, NCL-L-END, 1:200) with a Bond Polymer 
Refine detection system (Leica).
Statistics. Statistical analysis was performed using Prism 6 software (GraphPad). The data were 
analyzed by 1-way ANOVA with post hoc Tukey’s test or by Student’s unpaired 2-tailed t test as appro-
priate. P <0.05 was considered statistically significant.
Study approval. Informed consent was obtained from all patients, and the Royal Brisbane and Women’s 
Hospital human research ethics committee approved the clinical study protocol. All mouse experiments 
were approved by the University of  Newcastle animal ethics committee.
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